NOVEL COMBINATION OF A FACTOR XA INHIBITOR AND CLOPIDOGREL

摘要

The present application describes methods of using a combination of 1-(3'-aminobenzisoxazol-5'-yl)-3-trifluoromethyl-5-[[4-[(2'-dimethylaminomethyl)imidazol-1'-yl]-2-fluorophenyl]aminocarbonyl]pyrazole-hydrochloricacid salt, a factor Xa inhibitor, and Clopidogrel asanticoagulant agents for treatment of thromboembolic disorders and pharmaceutical compositions containing the same.